CFDE Data Portal | Search LRIG3-DT

	Label	Description
	LRIG3-DT Gene (Entity type)	ENSG00000257443 - LRIG3 divergent transcript
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 0 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 4 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 14 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 7 V 5 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE76425 0 V 12 LENALIDOMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE171692 FXN knockdown 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

LRIG3-DT

ENSG00000257443 - LRIG3 divergent transcript

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE226249 pirfenidone HL 0 v 7 human dn

A Gene Set from LINCS

GSE48812 sulforaphane 4 v 10 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 8 human up

A Gene Set from LINCS

GSE111247 temozolomide LN-308 14 v 12 human dn

A Gene Set from LINCS

GSE120612 7 V 5 ETOPOSIDE HUMAN UP

A Gene Set from LINCS

GSE76425 0 V 12 LENALIDOMIDE HUMAN UP

A Gene Set from LINCS

GSE171692 FXN knockdown 1 v 0 human up

A Gene Set from LINCS

GSE207410 GSE207411 ARID1A knockdown 5 v 3 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.